One study conducted by the New York University School of Medicine (NYU Grossman School of Medicine) has analyzed the resistance offered by vaccines to the delta variant of coronavirus. The results have shown that in the specific case of the brand of Janssen, of the American multinational Johnson & Johnson, could be five times less effective against this variant.
The investigation, called ‘Comparison of Neutralizing Antibody Titers 1 Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants’, they have carried it out Takuya Tada, Hao Zhou, Marie I. Samanovic, Belinda M. Dcosta, Amber Cornelius, Mark J. Mulligan and Nathaniel R. Landau, who have detected that antibodies generated by this vaccine in a significant fraction of those vaccinated “they had a low neutralizing titer”. The study has focused on these neutralizing antibodies and has not considered the long-lasting responses between immune cells that this vaccine stimulates.
A booster dose
The main author of the investigation, Nathaniel R. Landau, has affirmed to the television channel CNBC that the possibility of being immunizeds against coronavirus with the Janssen vaccine receive a second vaccine or other injectioni.e. a Janssen-branded booster or another Pfizer or Moderna puncture.
“The data underscore the importance of surveillance for breakthrough infections that cause COVID-19 severe and suggest the benefit of a second immunization after Ad26.COV2.S (Janssen) to increase protection against the variants, “the study authors said.
Jake Sargent, a Johnson & Johnson spokesperson, has claimed that the data presented on the research “They do not speak of the full nature of the immunological protection of the injection”. Sargent has also ensured that the vaccine generates a strong immune response that lasts for at least 8 months after inoculation.
Landau has responded in statements collected by Bloomberg that the results of the different studies are not differents, since they have found a reduced level of antibodies.